Copyright
©2014 Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Dec 21, 2014; 20(47): 17941-17948
Published online Dec 21, 2014. doi: 10.3748/wjg.v20.i47.17941
Published online Dec 21, 2014. doi: 10.3748/wjg.v20.i47.17941
Risk factors for early rebleeding and mortality in acute variceal hemorrhage
Jing-Run Zhao, Guang-Chuan Wang, Jin-Hua Hu, Chun-Qing Zhang, Department of Gastroenterology, Shandong Provincial Hospital Affiliated to Shandong University, Jinan 250021, Shandong Province, China
Jing-Run Zhao, Department of Gastroenterology, Liaocheng People’s Hospital, Liaocheng 252000, Shandong Province, China
Author contributions: Zhang CQ designed the research; Zhao JR, Hu JH and Wang GC collected the data and performed the research; Zhao JR and Hu JH analyzed the data and were responsible for the statistical work; Zhao JR drafted the article; Zhang CQ critically revised the manuscript for important intellectual content.
Correspondence to: Chun-Qing Zhang, MD, Department of Gastroenterology, Shandong Provincial Hospital Affiliated to Shandong University, No. 324 Jingwu Weiqi Road, Jinan 250021, Shandong Province, China. zhchqing@medmail.com.cn
Telephone: +86-531-66953227 Fax: +86-531-87906348
Received: May 13, 2014
Revised: July 16, 2014
Accepted: August 13, 2014
Published online: December 21, 2014
Processing time: 221 Days and 9.4 Hours
Revised: July 16, 2014
Accepted: August 13, 2014
Published online: December 21, 2014
Processing time: 221 Days and 9.4 Hours
Core Tip
Core tip: Acute variceal hemorrhage (AVH) is a medical emergency with a 20% mortality rate at 6 wk. Percutaneous transhepatic variceal embolization (PTVE) is a rescue therapy for endoscopic variceal ligation failure. Here we present a retrospective study to determine the risk factors for 6-wk rebleeding and mortality in AVH patients who have undergone PTVE. Patients with a model for end-stage liver disease score ≥ 18 and an HVPG ≥ 20 mmHg are at increased risk of death within 6 wk of an acute variceal bleeding episode. A transjugular intrahepatic portosystemic shunt or liver transplantation should be considered for this high-risk group.